FDA has cleared the Lucica Glycated Albumin-L, a specific intermediate glycemic control marker, for sale in the United States. The test is manufactured by Tokyo-based Asahi Kasei Pharma and sold exclusively by EKF Diagnostics, Cardiff, UK. It delivers a specific quantitative determination of glycated albumin (GA) in serum on compatible clinical chemistry analyzers with open channel capability.

Lucica Glycated Albumin-L offers several advantages:

  • It is specific for GA. It does not measure other glycated proteins such as glycated immunoglobulins.
  • The test measures both glycated albumin and total albumin in separate reactions.
  • Results are expressed as ratio, thus minimizing differences in protein concentrations between patients.

For more information, visit EKF Diagnostics.